Nifty

:

24435.95

Sensex

:

77966.35

-35.75 (-0.15%)
-187.90 (-0.24%)

Login

Nifty
Sensex

:
:

24435.95
77966.35

-35.75 (-0.15%)
-187.90 (-0.24%)

RPG Life Sciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :

71/99

BSE: 532983 | NSE: RPGLIFE

Watchlist

NSE BSE

2612.70

12-Aug-2026

Open
High
Low
Previous Close

2625
2645.8
2604
2633.40

Volume
Traded Value (lacs)
52 Week High
52 Week Low

6528
17100729.8
3082
1733

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

4,334.79
37.64
8

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

4,163.23
0.92%
6.81

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

9.19
9.96
6.72

EBITDA CAGR (%)

10 Years
5 Years
3 Years

17.85
11.17
2.77

PAT CAGR (%)

10 Years
5 Years
3 Years

25.28
17.47
9.52

P:E (Median)

8 Years
5 Years
3 Years

21.70
23.22
29.63

P:BV (Average)

8 Years
5 Years
3 Years

5.47
6.20
7.40

EV:EBITDA (Average)

8 Years
5 Years
3 Years

14.91
17.62
21.39

Earnings Forecasts:

(Updated: 08-08-2026)

Description 2026 2027 2028 2029
Adj EPS 54 -7 23.42 60
P/E Ratio 48.38 -373.24 111.56 43.55
Revenue 30.81 26.19 - 684.8
EBITDA 776.3 870.9 - 144.1
Net Income 180.9 212.5 - 99.3
ROA 128.5 151.2 - -
P/B Ratio - - - 7.80
ROE 6.03 5.09 - 18.4
FCFF 19.6 19.4 - 29.1
FCFF Yield 59.6 111.4 - 0.78
Net Debt 1.59 2.98 - -
BVPS - - - 335

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 26 Jun 25 Var% Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var%
Net Sales 195.69 168.92 15.85% 176.89 143.09 23.62% 180.03 172.71 4.24% 181.68 172.21 5.50%
Expenses 152.11 133.45 13.98% 144.02 117.60 22.47% 140.27 123.55 13.53% 142.65 126.28 12.96%
EBITDA 43.58 35.47 22.86% 32.87 25.49 28.95% 39.76 49.16 -19.12% 39.03 45.93 -15.02%
EBIDTM 22.27% 21.00% 18.58% 17.81% 22.09% 28.46% 21.48% 26.67%
Other Income 4.16 5.23 -20.46% 12.36 5.06 144.27% 3.41 3.31 3.02% 4.54 1.94 134.02%
Interest 0.63 0.13 384.62% 0.39 0.18 116.67% 0.25 0.12 108.33% 0.12 0.17 -29.41%
Depreciation 5.90 5.14 14.79% 5.74 5.37 6.89% 5.38 5.46 -1.47% 5.22 5.31 -1.69%
PBT 41.21 35.43 16.31% 40.20 134.90 -70.20% 29.12 46.89 -37.90% 49.45 15.09 227.70%
Tax 10.64 9.14 16.41% 10.30 17.55 -41.31% 6.99 11.96 -41.56% 12.60 10.89 15.70%
PAT 30.57 26.29 16.28% 29.90 117.35 -74.52% 22.13 34.93 -36.64% 36.85 4.20 777.38%
PATM 15.62% 15.56% 16.90% 82.01% 12.29% 20.22% 20.28% 2.44%
EPS 18.53 15.93 16.32% 18.12 71.12 -74.52% 13.41 21.17 -36.66% 22.33 2.55 775.69%

Description Jun 26 Jun 25 Var% Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var%
Net Sales 195.69 168.92 15.85% 176.89 143.09 23.62% 180.03 172.71 4.24% 0.00 0.00 0
Expenses 152.40 133.45 14.20% 144.06 117.60 22.50% 140.27 123.55 13.53% 0.00 0.00 0
EBITDA 43.29 35.47 22.05% 32.83 25.49 28.80% 39.76 49.16 -19.12% 0.00 0.00 0
EBIDTM 22.12% 21.00% 18.56% 17.81% 22.09% 28.46% 0.00% 0.00%
Other Income 4.70 5.23 -10.13% 12.40 5.06 145.06% 3.41 3.31 3.02% 0.00 0.00 0
Interest 0.63 0.13 384.62% 0.39 0.18 116.67% 0.25 0.12 108.33% 0.00 0.00 0
Depreciation 5.90 5.14 14.79% 5.74 5.37 6.89% 5.38 5.46 -1.47% 0.00 0.00 0
PBT 41.46 35.43 17.02% 40.20 134.90 -70.20% 29.12 46.89 -37.90% 0.00 0.00 0
Tax 10.70 9.14 17.07% 10.30 17.55 -41.31% 6.99 11.96 -41.56% 0.00 0.00 0
PAT 30.76 26.29 17.00% 29.90 117.35 -74.52% 22.13 34.93 -36.64% 0.00 0.00 0
PATM 15.72% 15.56% 16.90% 82.01% 12.29% 20.22% 0.00% 0.00%
EPS 18.60 15.90 16.98% 18.08 70.96 -74.52% 13.38 21.12 -36.65% 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description TTM Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Net Sales 734.29 707.52 653.43 582.05 512.81 440.16 389.14 375.57 330.16 343.95 293.64 Net Sales Growth 11.78% 8.28% 12.26% 13.50% 16.51% 13.11% 3.61% 13.75% -4.01% 17.13% Cost Of Goods Sold 260.22 233.22 196.65 167.82 156.64 127.59 121.27 119.63 103.93 106.87 96.02 Gross Profit 474.07 474.30 456.78 414.23 356.17 312.57 267.87 255.94 226.23 237.08 197.62 GP Margin 64.56% 67.04% 69.90% 71.17% 69.45% 71.01% 68.84% 68.15% 68.52% 68.93% 67.30% Total Expenditure 579.05 559.51 494.43 452.91 409.28 353.00 318.37 315.67 295.73 306.89 265.01 Power & Fuel Cost - 18.50 17.66 14.36 13.65 12.69 11.27 11.54 10.38 10.44 9.10 % Of Sales - 2.61% 2.70% 2.47% 2.66% 2.88% 2.90% 3.07% 3.14% 3.04% 3.10% Employee Cost - 141.48 126.14 132.15 117.06 99.97 94.66 90.97 89.93 90.14 75.59 % Of Sales - 20.00% 19.30% 22.70% 22.83% 22.71% 24.33% 24.22% 27.24% 26.21% 25.74% Manufacturing Exp. - 49.02 46.35 43.80 36.62 37.86 28.79 21.85 18.98 21.86 20.63 % Of Sales - 6.93% 7.09% 7.53% 7.14% 8.60% 7.40% 5.82% 5.75% 6.36% 7.03% General & Admin Exp. - 56.42 48.64 41.63 37.14 33.97 28.54 32.76 34.32 35.76 31.57 % Of Sales - 7.97% 7.44% 7.15% 7.24% 7.72% 7.33% 8.72% 10.39% 10.40% 10.75% Selling & Distn. Exp. - 42.94 46.22 37.85 35.62 32.27 25.47 20.13 18.61 22.51 17.90 % Of Sales - 6.07% 7.07% 6.50% 6.95% 7.33% 6.55% 5.36% 5.64% 6.54% 6.10% Miscellaneous Exp. - 17.93 12.77 15.30 12.55 8.65 8.37 18.79 19.58 19.31 17.90 % Of Sales - 2.53% 1.95% 2.63% 2.45% 1.97% 2.15% 5.00% 5.93% 5.61% 4.84% EBITDA 155.24 148.01 159.00 129.14 103.53 87.16 70.77 59.90 34.43 37.06 28.63 EBITDA Margin 21.14% 20.92% 24.33% 22.19% 20.19% 19.80% 18.19% 15.95% 10.43% 10.77% 9.75% Other Income 24.47 25.54 14.30 7.21 4.80 3.08 1.07 0.99 0.80 2.36 0.86 Interest 1.39 1.77 1.59 1.44 1.15 1.41 1.79 2.76 4.86 4.72 3.64 Depreciation 22.24 21.48 21.43 17.07 15.50 15.66 16.47 16.36 15.32 14.34 11.31 PBT 159.98 150.30 150.28 117.84 91.68 73.17 53.58 41.77 15.05 20.36 14.54 Tax 40.53 39.03 49.64 30.18 24.04 21.69 13.58 7.44 4.24 6.91 2.45 Tax Rate 25.33% 25.31% 21.32% 25.61% 26.22% 29.64% 25.35% 20.41% 28.17% 33.94% 16.85% PAT 119.45 115.17 183.24 87.66 67.64 51.48 40.00 29.01 10.81 13.45 12.09 PAT before Minority Interest 119.45 115.17 183.24 87.66 67.64 51.48 40.00 29.01 10.81 13.45 12.09 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 16.27% 16.28% 28.04% 15.06% 13.19% 11.70% 10.28% 7.72% 3.27% 3.91% 4.12% PAT Growth -34.64% -37.15% 109.03% 29.60% 31.39% 28.70% 37.88% 168.36% -19.63% 11.25% EPS 72.39 69.80 111.05 53.13 40.99 31.20 24.24 17.58 6.55 8.15 7.33

Description TTM Mar 26 Mar 25
Net Sales - 707.52 653.43 Net Sales Growth - 8.28% Cost Of Goods Sold - 233.22 196.65 Gross Profit - 474.30 456.78 GP Margin - 67.04% 69.90% Total Expenditure - 559.55 494.46 Power & Fuel Cost - 18.50 17.66 % Of Sales - 2.61% 2.70% Employee Cost - 141.48 126.14 % Of Sales - 20.00% 19.30% Manufacturing Exp. - 49.02 46.35 % Of Sales - 6.93% 7.09% General & Admin Exp. - 56.52 48.64 % Of Sales - 7.99% 7.44% Selling & Distn. Exp. - 42.94 46.22 % Of Sales - 6.07% 7.07% Miscellaneous Exp. - 17.87 12.80 % Of Sales - 2.53% 1.96% EBITDA - 147.97 158.97 EBITDA Margin - 20.91% 24.33% Other Income - 25.58 14.33 Interest - 1.77 1.59 Depreciation - 21.48 21.43 PBT - 150.30 150.28 Tax - 39.03 49.64 Tax Rate - 25.31% 21.32% PAT - 115.17 183.24 PAT before Minority Interest - 115.17 183.24 Minority Interest - 0.00 0.00 PAT Margin - 16.28% 28.04% PAT Growth - -37.15% EPS - 69.80 111.05

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Shareholder's Funds 605.37 530.53 374.85 307.60 255.77 216.45 176.57 160.50 154.75 147.01 Share Capital 13.23 13.23 13.23 13.23 13.23 13.23 13.23 13.23 13.23 13.23 Total Reserves 592.14 517.30 361.62 294.37 242.54 203.22 163.34 147.27 141.52 133.78 Non-Current Liabilities 27.24 6.45 6.48 8.97 8.73 7.19 8.75 9.58 8.37 10.77 Secured Loans 13.33 0.00 0.00 0.00 0.01 0.08 0.22 4.63 10.11 15.89 Unsecured Loans 0.00 0.00 0.00 0.00 0.29 0.66 1.30 1.95 0.12 0.16 Long Term Provisions 7.41 4.54 4.03 3.98 3.04 3.13 8.50 6.19 2.79 2.32 Current Liabilities 160.53 119.83 130.96 102.78 80.11 79.69 82.59 77.82 120.71 78.68 Trade Payables 97.21 79.39 71.02 64.69 45.50 47.44 44.41 25.13 51.87 28.65 Other Current Liabilities 32.97 24.33 45.05 26.23 19.87 18.12 20.30 13.32 18.47 14.91 Short Term Borrowings 0.00 0.00 0.00 0.00 0.21 0.52 5.12 29.04 37.92 24.01 Short Term Provisions 30.35 16.11 14.89 11.86 14.53 13.61 12.76 10.33 12.45 11.11 Total Liabilities 793.14 656.81 512.29 419.35 344.61 303.33 267.91 247.90 283.83 236.46 Net Block 196.54 171.83 113.53 124.26 103.71 113.30 122.89 127.64 130.80 136.67 Gross Block 321.10 276.05 221.52 220.01 186.37 180.44 173.81 162.55 150.65 142.43 Accumulated Depreciation 124.56 104.22 107.99 95.75 82.66 67.14 50.92 34.91 19.85 5.76 Non Current Assets 268.45 191.56 214.20 155.30 137.70 127.48 142.13 150.81 141.21 140.08 Capital Work in Progress 23.29 16.06 96.31 25.44 31.06 11.77 9.98 17.17 8.73 1.82 Non Current Investment 35.79 1.01 1.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 12.83 2.66 3.35 5.60 2.93 2.41 9.26 6.00 1.68 1.59 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 524.69 465.25 298.09 264.05 206.91 175.85 125.78 97.09 142.62 96.38 Current Investments 83.90 125.90 90.15 58.43 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 123.84 92.98 101.00 95.05 82.99 58.33 46.61 41.04 53.69 45.78 Sundry Debtors 116.68 86.76 49.13 37.43 32.99 57.42 63.33 38.90 68.13 39.28 Cash & Bank 156.78 139.61 36.47 57.04 70.26 40.75 1.11 0.77 0.94 1.60 Other Current Assets 43.49 10.11 4.86 5.41 20.67 19.35 14.73 16.38 19.86 9.72 Short Term Loans & Adv. 27.92 9.89 16.48 10.69 14.03 10.64 6.51 9.45 12.26 4.13 Net Current Assets 364.16 345.42 167.13 161.27 126.80 96.16 43.19 19.27 21.91 17.70 Total Assets 793.14 656.81 512.29 419.35 344.61 303.33 267.91 247.90 283.83 236.46

Description Mar 26 Mar 25
Shareholder's Funds 605.35 530.53 Share Capital 13.23 13.23 Total Reserves 592.12 517.30 Non-Current Liabilities 27.24 6.45 Secured Loans 13.33 0.00 Unsecured Loans 0.00 0.00 Long Term Provisions 7.41 4.54 Current Liabilities 160.57 119.83 Trade Payables 97.25 79.39 Other Current Liabilities 32.97 24.33 Short Term Borrowings 0.00 0.00 Short Term Provisions 30.35 16.11 Total Liabilities 793.16 656.81 Net Block 196.54 171.83 Gross Block 321.10 276.05 Accumulated Depreciation 124.56 104.22 Non Current Assets 233.68 191.56 Capital Work in Progress 23.29 16.06 Non Current Investment 1.01 1.01 Long Term Loans & Adv. 12.84 2.66 Other Non Current Assets 0.00 0.00 Current Assets 559.48 465.25 Current Investments 83.90 125.90 Inventories 123.84 92.98 Sundry Debtors 116.68 86.76 Cash & Bank 191.56 139.61 Other Current Assets 43.50 10.11 Short Term Loans & Adv. 27.92 9.89 Net Current Assets 398.91 345.42 Total Assets 793.16 656.81

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Cash From Operating Activity 56.50 77.86 94.36 90.82 64.75 58.27 50.17 45.78 14.68 7.33 PBT 154.20 232.88 117.84 91.68 73.17 53.58 36.45 15.05 20.36 23.46 Adjustment -17.31 -76.22 12.92 13.31 13.54 16.55 22.52 20.08 17.37 6.95 Changes in Working Capital -43.18 -26.05 -7.09 11.06 -3.11 -3.53 -2.37 14.37 -19.35 -18.81 Cash after chg. in Working capital 93.71 130.61 123.67 116.05 83.60 66.60 56.60 49.50 18.38 11.60 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -37.21 -52.75 -29.31 -25.23 -18.85 -8.33 -6.43 -3.72 -3.70 -4.27 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 51.06 -41.80 -79.15 -105.81 -34.66 -7.96 -10.70 -19.02 -15.54 -30.06 Net Fixed Assets -52.28 25.72 -72.38 -28.02 -25.22 -8.42 -4.07 -20.34 -15.13 47.17 Net Investments 7.22 -35.75 -32.73 -58.43 0.00 0.00 0.00 0.00 0.00 0.00 Others 96.12 -31.77 25.96 -19.36 -9.44 0.46 -6.63 1.32 -0.41 -77.23 Cash from Financing Activity -20.58 -27.08 -20.31 -17.12 -13.51 -10.49 -39.30 -26.50 0.11 23.36 Net Cash Inflow / Outflow 86.98 8.98 -5.10 -32.11 16.58 39.82 0.17 0.26 -0.75 0.63 Opening Cash & Equivalents 28.70 19.72 24.82 56.93 40.36 0.54 0.37 0.11 0.86 0.23 Closing Cash & Equivalent 115.68 28.70 19.72 24.82 56.94 40.36 0.54 0.37 0.11 0.86

Description Mar 26 Mar 25
Cash From Operating Activity 56.50 77.86 PBT 154.20 232.88 Adjustment -17.31 -76.22 Changes in Working Capital -43.17 -26.05 Cash after chg. in Working capital 93.72 130.61 Interest Paid 0.00 0.00 Tax Paid -37.22 -52.75 Other Direct Exp. Paid 0.00 0.00 Extra & Other Items 0.00 0.00 Cash From Investing Activity 85.84 -41.80 Net Fixed Assets -52.28 Net Investments 7.22 Others 130.90 Cash from Financing Activity -20.58 -27.08 Net Cash Inflow / Outflow 121.76 8.98 Opening Cash & Equivalents 28.70 19.72 Closing Cash & Equivalent 150.46 28.70

Financial Ratios

Standalone /

Consolidated

Right to Left

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Book Value (Rs.) 366.06 320.80 226.67 186.00 154.66 130.88 106.77 97.05 93.58 88.89 ROA 15.89% 31.35% 18.82% 17.71% 15.89% 14.00% 11.25% 4.07% 5.17% 9.15% ROE 20.28% 40.48% 25.69% 24.01% 21.80% 20.36% 17.21% 6.86% 8.91% 14.98% ROCE 26.99% 51.79% 34.96% 32.92% 31.46% 27.27% 20.35% 9.81% 12.52% 15.58% Fixed Asset Turnover 2.53 2.82 2.83 2.73 2.61 2.37 2.23 2.11 2.37 1.85 Receivable days 49.08 35.40 25.32 23.17 34.41 52.52 49.68 59.16 56.47 45.37 Inventory Days 52.31 50.53 57.35 58.57 53.79 45.64 42.59 52.36 52.29 50.44 Payable days 138.19 139.59 147.58 128.38 132.94 138.23 44.01 56.38 53.51 47.24 Cash Conversion Cycle -36.81 -53.67 -64.92 -46.65 -44.74 -40.07 48.25 55.15 55.25 48.57 Total Debt/Equity 0.03 0.00 0.00 0.00 0.00 0.01 0.07 0.23 0.35 0.30 Interest Cover 88.12 147.47 82.83 80.72 52.89 30.93 14.21 4.10 5.31 7.45

Description Mar 26 Mar 25
Book Value (Rs.) 366.05 320.80 ROA 15.89% 27.90% ROE 20.28% 34.54% ROCE 26.99% 44.20% Fixed Asset Turnover 2.53 2.54 Receivable days 49.08 45.20 Inventory Days 52.31 48.44 Payable days 138.22 147.35 Cash Conversion Cycle -36.84 -53.72 Total Debt/Equity 0.03 0.00 Interest Cover 88.12 147.47

Top Investors:

clarus capital i

authum investment and infrastructure limited

investor education and protection fund authority ministry of corporate affairs

Annual Reports:

News Update:

RPG Life Sciences partners with Archerchem
13th Jul 2026, 15:27 PM

The launch aligns with the company’s continued focus on building a differentiated portfolio in chronic therapy segments.
Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback